Exelixis, Storm join up in collaboration and license agreement; Teligent files for bankruptcy
Exelixis and RNA-focused biotech Storm Therapeutics entered into an exclusive collaboration and license agreement, the companies jointly announced today.
The deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
